Meeting
2020 Gastrointestinal Cancers Symposium
Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149.
Authors
Nataliya Volodymyrivna Uboha
University of Wisconsin, Carbone Cancer Center, Madison, WI
Nataliya Volodymyrivna Uboha , Jens C. Eickhoff , Chandrikha Chandrasekharan , Shadia Ibrahim Jalal , Al Bowen Benson III, Dustin A. Deming , Stephen Lindemann , Howard S. Hochster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03997448
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr TPS461)
Abstract #
TPS461
Poster Bd #
L5
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3.
First Author: Samuel J Klempner
Poster
2023 ASCO Annual Meeting
A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.
First Author: Montaser F. Shaheen
Poster
2023 ASCO Annual Meeting
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
First Author: Bernard Doger de Spéville
Poster
2023 ASCO Annual Meeting
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.
First Author: Jeremy Meyer Force